Use of Oncotype DX in Women with Node-Positive Breast Cancer.
Use of Oncotype DX in Women with Node-Positive Breast Cancer.
复制标题
DOI：
10.1371/currents.rrn1249
复制
发表时间：
2011-07-21
期刊：
影响因子：
--
通讯作者：
Ramsey, Scott David
中科院分区：
文献类型：
--
作者：
Ishibe, Naoko;Schully, Sheri;Ramsey, Scott David
早期乳腺癌患者经常接受辅助化疗以预防复发;然而，并非所有患者都受益。最近，可以更好地预测乳腺癌复发风险的基因表达标记物面板，如Oncotype DX，已经商业化，并被用于指导治疗决策。Oncotype DX分析了肿瘤内21个基因的表达，以确定复发评分，该评分对应于初次诊断后10年内乳腺癌复发的特定可能性，以及对辅助治疗的反应。我们对已发表的文献进行了分析有效性、临床有效性和Oncotype DX在指导淋巴结阳性乳腺癌女性辅助治疗决策中的临床效用的研究。
Women with early stage breast cancer frequently receive adjuvant chemotherapy to prevent recurrence; however, not all patients benefit. Recently, gene expression marker panels, such as Oncotype DX, that may better predict risk of breast cancer recurrence have become commercially available and are being used to guide treatment decisions. Oncotype DX analyzes the expression of 21 genes within a tumor to determine a recurrence score that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis, as well as response to adjuvant treatment. We examined the published literature on the analytic validity, clinical validity, and clinical utility of Oncotype DX in guiding adjuvant treatment decisions in women with lymph node-positive breast cancer.